Category Archives: Tekturna

Featured Stories
Older Patients Face Heart Attack Risk Following Surgery

Older Hip Implant, Knee Replacement Patients Face Heart Attack Risk Following Surgery

An emerging report reveals that older hip implant and knee replacement patients face increased heart attack risks following surgery. The risk for acute myocardial infarction (AMI) was seen in the first two weeks after these surgical procedures.

Read More

Smith & Nephew Says Metal-on-Metal Hip Replacement Controversy Slowing Sales of Birmingham Hip Resurfacing System

Medical device maker Smith & Nephew has reported a drop in sales of its metal-on-metal hip implant devices. According to the company, hip implant sales were down 2 percent during the first quarter of 2012, largely because its Birmingham Hip Resurfacing System suffered from an association with other metal-on-metal hip ...

Read More

DeflateGate’s Effects Impact Legal Gambling and the Economy

DeflateGate’s Effects Impact Legal Gambling and the Economy

The NFL has initiated a probe into the New England Patriots following allegations that the team intentionally used overly deflated footballs.

Read More

British Recall of Smith & Nephew Renasys Wound Care System

British Recall of Smith & Nephew Renasys Wound Care System for Infection Risk

The MHRA announced the recall of Smith & Nephew Renasys wound care devices - risk of maceration, infection, loss of negative pressure, or unrecognized bleeding in wounds.

Read More

Fracking Should be Kept 600m From Aquifers, Study Says

New research on the safety of hydraulic fracturing (fracking) suggests new wells should not be dug within 600 meters of a water aquifer because underground fractures can extend about that far from a dug well. According to a report from UK’s The Guardian newspaper, researchers and geologists at Durham University have ...

Read More

New York City Council Calls for Zadroga Act to be Renewed

New York City Council Calls for Zadroga Act to be Renewed

New York City Council members are calling for the Zadroga Act, which provides compensation and medical treatment to 9/11 victims, to be renewed. According to press release issued Jan. 7, a resolution was introduced by Council Member Margaret Chin, Council Speaker Melissa Mark-Viverito and Council Members Paul Vallone and I. ...

Read More

Actos Side Effects Lawyers Says Whistleblower Revelations Could Boost Bladder Cancer, Heart Failure Lawsuits

An attorney with a prominent personal injury law firm says an Actos whistleblower lawsuit filed earlier this year could strengthen legal claims alleging the type 2 diabetes medication caused some users to develop bladder cancer and heart failure.

Read More

Tennessee Resident Files Pradaxa Bleeding Lawsuit Following Cerebral Hemorrhage

A man from Tennessee has filed a lawsuit against the maker of Pradaxa, claiming that the blood thinner caused him to suffer a cerebral hemorrhage. The complaint alleges Boehringer Ingelheim Pharmaceuticals, Inc. concealed knowledge that Pradaxa can cause Serious, life-threatening bleeds, and did not warn that Pradaxa bleeding side effects ...

Read More

Pradaxa Named in Most FDA Adverse Event Reports for Deaths, Hemorrhage, Kidney Failure and Stroke

The controversial blood thinner, Pradaxa, surpassed all other drugs monitored by the U.S. Food & Drug Administration (FDA) in adverse event reports made to the agency last year. According to the Institute for Safe Medicine Practices’ (ISMP) latest QuarterWatch report, Pradaxa also topped the list for reports of deaths, ...

Read More

Drug Maker, Novartis, Accused Again of Kickback Schemes

We have long noted that the financial relationships between the drug and the health care industries have led to enormous controversy. Critics maintain that such relationships create conflicts of interest and could unduly influence everything from research findings to prescribing … Continue reading

Posted in Consumer Fraud, Legal News, Pharmaceuticals, Tekturna |

U.S. Prosecutors Investigating Novartis Marketing of Blood Pressure Drug Tekturna

U.S. prosecutors are investigating European drug manufacturer Novartis for its marketing of products including hypertension drug Tekturna. In a recent regulatory filing, Swiss-based Novartis revealed that, last year, a U.S. unit of the company received a subpoena from federal prosecutors … Continue reading

Posted in Health Concerns, Legal News, Pharmaceuticals, Tekturna |

Analysis of adverse event reports questions benefit of blood pressure drug Tekturna

A recent analysis of adverse health events linked to certain prescription drugs identified 100 incidents linked to the blood pressure medication Tekturna in just the first part of this year. The Institute for Safe Medication Practices (ISMP) combed a database … Continue reading

Posted in Pharmaceuticals, Tekturna | Tagged |

Tekturna Linked to Significant Number of Adverse Events

Independent watchdog group, the Institute for Safe Medical Practices (ISMP) reports a 90 percent increase in significant adverse drug event reports received by the U.S. Food & Drug Administration (FDA) over the past four years. Among these, are events associated … Continue reading

Posted in Pharmaceuticals, Tekturna |

Tekturna Label Changes, Valturna Market Withdrawal Announced by Novartis

Novartis announced yesterday that the label for the blood pressure drug Tekturna (aliskiren) will be updated with new warnings regarding its use in people with diabetes and kidney problems. Novartis also announced it will no longer market Valturna, a single-pill … Continue reading

Posted in Pharmaceuticals, Tekturna | Tagged |

Tekturna (Aliskiren) Associated with Serious Side Effects, Including Stroke, Severe Kidney Damage

Tekturna (aliskiren) and other medications containing aliskiren have been associated with serious side effects, including non-fatal stroke and severe kidney damage, in some patients. Tekturna and other aliskiren products were recently the subject of safety warnings in Europe (where it … Continue reading

Posted in Pharmaceuticals, Tekturna | Tagged |

MHRA Issues New Contraindications, Recommendations for Rasilez (Aliskiren) with ACE Inhibitors, ARBs

Health regulators in the U.K. have announced new contraindications and warnings regarding Rasilez (aliskiren), a blood pressure drug which is sold as Tekturna in the U.S. According a Drug Safety Update issued by the Medicine and Healthcare Products Regulatory Agency, … Continue reading

Posted in Pharmaceuticals, Tekturna |

Novartis Updates Rasilez Label in Europe with New Warnings for Diabetes, Kidney Patients

The blood pressure drug Rasilez – sold in the U.S. under the brand name Tekturna – will soon bear new safety warnings on its European label, after a clinical trial was halted because subject patients experienced a high rate of … Continue reading

Posted in Pharmaceuticals, Tekturna |

Canada Issues Warning, Updates Labeling For Rasilez

Canada just issued a warning for Rasilez, a high blood pressure drug known as Tekturna in the United States. Novartis Pharmaceuticals, Canada Inc makes Rasilez. Health Canada and Novartis issued the warning for aliskiren-containing products, Rasilez and Rasilez HCT, after … Continue reading

Posted in Pharmaceuticals, Tekturna |

Tekturna To Undergo Canadian Safety Review

High blood pressure drug, Tekturna, will undergo a Canadian Safety Review after a clinical study was halted by drug maker, Novartis, over unexpected adverse reactions. “Specifically, when used in combination with other blood pressure-lowering drugs known as angiotensin-converting enzyme (ACE) … Continue reading

Posted in Tekturna |

© 2005-2018 Parker Waichman LLP ®. All Rights Reserved.